Cassava Sciences, Inc.: Allegations of data manipulation in simufilam Alzheimer’s drug clinical trials

March 8, 2026 •

The 'Breakthrough' Narrative: Simufilam's Phase 2b Data and Market Reaction The story of Cassava Sciences and its Alzheimer’s drug, simufilam, begins not with a discovery,…